Publicaciones en las que colabora con A.P. Berbegall (35)

2022

  1. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes

    Neoplasia (United States), Vol. 23, Núm. 1, pp. 12-20

  2. Intra-tumour genetic heterogeneity and prognosis in high-risk neuroblastoma

    Cancers, Vol. 13, Núm. 20

2020

  1. 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma

    Cell Reports, Vol. 32, Núm. 12

  2. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report from the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

    Journal of Clinical Oncology, Vol. 38, Núm. 31, pp. 3685-3697

  3. Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line

    Journal of Experimental and Clinical Cancer Research, Vol. 39, Núm. 1

2019

  1. Aplicaciones de modelos 3D bioimpresos: Aproximación terapéutica en neuroblastoma

    Innovación Docente e Investigación en Ciencias de la Salud (Dykinson), pp. 663-670

  2. Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis

    International Journal of Surgical Pathology, Vol. 27, Núm. 5, pp. 568-573

2018

  1. 1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors

    Histology and Histopathology, Vol. 33, Núm. 5, pp. 487-495

  2. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma

    Anti-Cancer Drugs, Vol. 29, Núm. 8, pp. 717-724

  3. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

    JCI insight, Vol. 3, Núm. 23

  4. Heterogeneous MYCN amplification in neuroblastoma: A SIOP Europe Neuroblastoma Study

    British Journal of Cancer, Vol. 118, Núm. 11, pp. 1502-1512

  5. Lymph microvascularization as a prognostic indicator in neuroblastoma

    Oncotarget, Vol. 9, Núm. 40, pp. 26157-26170

  6. Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma

    Cancer Research, Vol. 78, Núm. 20, pp. 5958-5969

2017

  1. A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors

    Pediatric Blood and Cancer, Vol. 64, Núm. 9

2016

  1. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors

    Oncogene, Vol. 35, Núm. 11, pp. 1423-1432

  2. Diagnostic implications of intrapatient genetic tumor heterogeneity

    Molecular and Cellular Oncology, Vol. 3, Núm. 2

  3. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort

    British Journal of Cancer, Vol. 115, Núm. 4, pp. 480-489

  4. Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood

    Expert Review of Neurotherapeutics

  5. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma

    Oncotarget, Vol. 7, Núm. 2, pp. 1960-1972